|
?:authorAffiliation
|
-
[\'Universidad de Alcalá, Medical Oncology Department, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain. Electronic address: pilargarrido@gmail.com.\', \'Mayo Clinic, Rochester, USA.\', \'Tata Memorial Centre, Mumbai, India.\', \'The Royal Marsden NHS Foundation Trust, Institute of Cancer Research, London, UK.\', \'Division of Oncology, Department of Medicine 1, Medical University of Vienna, Vienna, Austria.\', \'Curie Oncology Singapore, National Cancer Centre Singapore, Singapore.\', \'Medical Oncology Department, Vall d\'Hebron University Hospital, Thoracic Oncology and H&N Cancer Unit, Vall d\'Hebron Institute of Oncology (VHIO), UVic-UCC, Barcelona, Spain.\', \'Royal Marsden NHS Foundation Trust, London, UK.\', \'Early Drug Development Unit, VHIO - Vall d\'Hebron Institute of Oncology, HUVH - Vall d\'Hebron University Hospital, Barcelona, Spain.\', \'Division of Medical Oncology, The Netherlands Cancer Institute (NKI), Amsterdam, Netherlands.\', \'Department of Medicine II, Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany.\', \'4th Oncology Department, Metropolitan Hospital, Athens, Greece.\', \'Oncology Department - CHUV, Lausanne University, Lausanne.\', \'Ente Ospedaliero Cantonale, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.\', \'Medical Oncology Department, Vall d\'Hebron University Hospital (HUVH), Vall d\'Hebron Institute of Oncology (VHIO), UVic-UCC, Barcelona, Spain.\', \'Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.\', \'Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.\', \'Thoracic Oncology Unit, Medical Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}